PPIDT00456
Drug Information
| Name | Imdevimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15940 |
| Type | biotech |
| Indication | According to the Emergency Use Authorization (EUA) by the FDA and EMA, indevimab is used only with casirivimab to prevent COVID-19 and treat mild to moderate COVID-19 from laboratory-confirmed SARS-CoV-2 infection in patients aged 12 years of age and older who weigh at least 40 kg. Treatment is reserved for patients who are at high risk for progressing to require hospitalization or severe COVID-19.[L23524,L23534,L39135] This combination may only be administered by intravenous infusion in healthcare settings with immediate access to treatment for infusion reactions and anaphylaxis, and the ability to activate the emergency medical system (EMS), as required.[L23534,L23539] **Limitations of use** Imdevimab and casirivimab are not for use in patients currently hospitalized due to COVID-19, patients requiring oxygen therapy due to COVID-19, patients requiring increases in baseline oxygen flow rate from COVID-19, or patients on oxygen therapy for non-COVID-19 related morbidity.[L23524,L23534] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Intravenous |
|
| Injection, solution, concentrate; kit | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
1332 mg/11.1mL
|
| Injection, solution, concentrate | Intravenous |
300 mg/2.5mL
|
| Injection | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
|
| Injection, solution | Intravenous; Subcutaneous |
|